01—Abstract
Summary
Summary of the 10-Q filed May 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals Inc. reported strong financial performance for the first quarter of 2026, with total revenues increasing by 8% to $2,986.9 milliona compared to the same period in 2025.
This growth was primarily driven by the continued strength of its cystic fibrosis (CF) therapies, particularly ALYFTREK and TRIKAFTA/KAFTRIO, and initial contributions from newer products like CASGEVY and JOURNAVX. Net income saw a significant surge of approximately 59.5% to $1,031.4 millionb, driven by robust revenue growth and a reduction in total costs and expenses, notably due to the absence of a large intangible asset impairment charge recorded in the prior year. The company also maintained a healthy cash position, with cash, cash equivalents, and marketable securities totaling $12,996.6 million, indicating strong liquidity and financial stability to support ongoing research, development, and commercialization efforts.
02—Key points
Key Highlights
- Total revenues increased by 8% to $2,986.9 million in Q1 2026 compared to Q1 2025.
- Net income significantly grew by 59.5% to $1,031.4 million in Q1 2026.
- Product revenues from CF therapies, especially ALYFTREK and TRIKAFTA/KAFTRIO, remain strong, with ALYFTREK showing substantial year-over-year growth.
- CASGEVY contributed $42.9 million in product revenue, a significant increase from $14.2 million in Q1 2025.
- Total costs and expenses decreased by 14% to $1,848.8 million, largely due to the absence of a $379 million intangible asset impairment charge recorded in Q1 2025.
- The company's cash, cash equivalents, and marketable securities increased to $12,996.6 million as of March 31, 2026, reflecting strong liquidity.
- Vertex continues to invest heavily in R&D, with expenses totaling $961.6 million, supporting a diversified pipeline.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2026, Vertex Pharmaceuticals Inc kept $0.35.
- Revenue$2.99B100.0%
- Cost of revenue−$392.8M13.2%
- Gross profit$2.59B86.8%
- Operating costs−$1.46B48.7%
- Operating income$1.14B38.1%
- Interest, other & tax−$106.7M3.6%
- Net income$1.03B34.5%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2026filed May 5, 2026Financial Statements
Q1 FY2026 against Q1 FY2025
| Line item | Q1 FY2026Q1 FY2025 | Change |
|---|---|---|
| Revenue | $2.99B$2.77B | +7.8% |
| Cost of Revenue | $392.80M$363.00M | +8.2% |
| Gross Profit | $2.59B$2.41B | +7.8% |
| SG&A Expenses | $493.70M$396.40M | +24.5% |
| Operating Expenses | $1.85B$2.14B | −13.6% |
| Operating Income | $1.14B$630.10M | +80.6% |
| Net Income | $1.03B$646.30M | +59.6% |
| EPS (Basic) | $4.06$2.52 | +61.1% |
| EPS (Diluted) | $4.02$2.49 | +61.4% |
| Shares Outstanding (Basic) | 254.10M256.90M | −1.1% |
| Shares Outstanding (Diluted) | 256.30M259.50M | −1.2% |
05—Questions
Frequently Asked Questions
What were the main drivers of revenue growth in Q1 2026?
Revenue growth was primarily driven by the continued strong performance of Vertex's cystic fibrosis (CF) therapies, particularly ALYFTREK and TRIKAFTA/KAFTRIO. Diversification into new disease areas also contributed, with notable revenue increases from CASGEVY (for sickle cell disease and beta thalassemia) and JOURNAVX (for acute pain).
How did the company's profitability change compared to the previous year?
Profitability saw a substantial improvement, with net income increasing by 59.5% to $1,031.4 million in Q1 2026. This was due to strong revenue growth and a significant decrease in total costs and expenses, largely because the prior year's quarter included a substantial intangible asset impairment charge.
What is the company's financial position regarding liquidity?
Vertex maintains a strong liquidity position, with total cash, cash equivalents, and marketable securities reaching $12,996.6 million as of March 31, 2026. This robust balance provides ample resources to fund operations, ongoing research and development, and strategic initiatives.
Are there any significant legal or contingent matters impacting the company?
The company is involved in a confidential arbitration with Royalty Pharma plc (RP) regarding the royalty burden for ALYFTREK. RP alleges a higher royalty rate than Vertex's position. Vertex intends to vigorously defend its stance. However, no material loss contingencies were accrued as of March 31, 2026.
06—Continue